Patients and Caregivers
The PHA-Accredited PH Care Centers (PHCC) program is an initiative of PHA’s Scientific Leadership Council to accredit centers in the U.S. in order to raise the level of care for individuals with pulmonary hypertension (PH). Accreditation is based on a center’s overall commitment to PH patients, breadth of involved health care professionals and scope of services provided.
How to Find a PH Specialist In the PHCC Network
PHA has created two maps to assist in locating a PHCC near you.
PH specialists in the PHCC network also can be found in our Doctors Who Treat PH directory. They will be designated as part of an accredited PH program in your search.
How PH Care Centers Are Expected to Improve Your Medical Care
- Patients are better informed about comprehensive PH care
- Patients have improved access to Centers with expertise in PH
- Patients experience less time between symptom onset and diagnosis
- A medical community better informed about standards of PH care
- Therapies are appropriately used to improve long-term outcomes
- Increased opportunities for collaboration between Centers for clinical care and PH research
The Two Types of Centers
Two types of centers are accredited: Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP). Both accredited CCCs and RCPs will have demonstrated a commitment to providing expert-level care based on pulmonary arterial hypertension (PAH) consensus guidelines.
Centers of Comprehensive Care
A PHA-Accredited Center of Comprehensive Care is a highly organized, full-time PH Center that proficiently evaluates PH patients based on published evidence-based guidelines and also provides expert treatment of pulmonary arterial hypertension (PAH) patients with all of the FDA-approved therapies. CCCs also make important contributions to PH research and education.
Regional Clinical Programs
A PHA-Accredited Regional Clinical Program is a regional PH Center that proficiently evaluates PH patients based on published evidence-based guidelines and also provides expert treatment of PAH patients with all non-parenteral therapies. An RCP must collaborate with its regional CCCs by referring patients that may benefit from opportunities unavailable at the RCP, including the initiation of advanced parenteral therapies and participation in clinical research protocols.
Developing and Implementing the PHCC Program
In September 2011, members of the PHA Board of Trustees, the PHA Scientific Leadership Council, and other key stakeholders in the PH community approved the PHCC initiative in concept. A steering committee and task forces were organized and staffed to address accreditation criteria, program implementation, registry development, communication to key stakeholders and financial sustainability. The members below provided valuable contributions, which include: researching, accumulating and documenting information, developing logic models, defining action steps, building financial projections and validating the program content.
|Murali Chakinala, MD (PHCC Chair)||Washington University in Saint Louis|
|Richard Channick, MD||Harvard Medical School|
|C. Gregory Elliott, MD||University of Utah|
|Serpil Erzurum, MD||The Cleveland Clinic Foundation|
|Karen Fagan, MD||University of South Alabama|
|Michael Patrick Gray, MPH||PHA|
|Wendy Hill, RN, MSN||VA Greater LA Healthcare System|
|Steven Kawut, MD, MS (Patient Registry Task Force Chair)||University of Pennsylvania|
|Vallerie McLaughlin, MD||University of Michigan|
|Stephen Mathai, MD, MHS||Johns Hopkins University|
|Olivia Onyeador, MHA||PHA|
|Ron Oudiz, MD (Criteria Task Force Chair)||Harbor UCLA Medical Center|
|Abby Poms, RRT, RCP (Implementation Task Force Co-Chair)||Duke University|
|Jeffrey Sager, MD, MSCE||Cottage Hospital|
|Robert Schilz, DO, PhD||Case Western Reserve University|
|Traci Stewart, RN, MSN||University of Iowa|
|Darren Taichman, MD||University of Pennsylvania|
|Victor Tapson, MD||Cedars-Sinai|
|Corey Ventetuolo, MD, MS||Brown University|
|Joel Wirth, MD (Implementation Task Force Co-Chair)||Maine Medical Center|
|Roham Zamanian, MD (Funding Task Force Chair)||Stanford University|